<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6901432/results/search/disease/results.xml">
  <result pre="Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus" exact="Type 1" post="and 2 MichaelisMartin1KleinschmidtMalte C.2BojkovaDenisa2RabenauHolger F.2WassMark N.1Cinatl Jr.Jindrich2*[], 1Industrial Biotechnology"/>
  <result pre="Omeprazole did not affect the antiviral effects of ribavirin in" exact="non-toxic" post="concentrations up to 80 μg/mL but increased the acyclovir-mediated"/>
  <result pre="up to 80 μg/mL but increased the acyclovir-mediated effects on" exact="herpes" post="simplex virus 1 and 2 (HSV-1 and -2) replication"/>
  <result pre="effects on acyclovir activity and also increased acyclovir activity at" exact="lower" post="concentrations that did not directly interfere with HSV replication."/>
  <result pre="frequently prescribed drugs for the treatment and prophylaxis of gastroesophageal" exact="reflux" post="as well as of gastric and duodenal ulcers that"/>
  <result pre="and its pro-drug valacyclovir are used for the treatment of" exact="disease" post="caused by herpes simplex virus 1 (HSV-1) and 2"/>
  <result pre="valacyclovir are used for the treatment of disease caused by" exact="herpes" post="simplex virus 1 (HSV-1) and 2 (HSV-2) and varicella"/>
  <result pre="by herpes simplex virus 1 (HSV-1) and 2 (HSV-2) and" exact="varicella" post="zoster virus (VZV) (Zarrouk et al., 2017). Acyclovir is"/>
  <result pre="herpes simplex virus 1 (HSV-1) and 2 (HSV-2) and varicella" exact="zoster" post="virus (VZV) (Zarrouk et al., 2017). Acyclovir is activated"/>
  <result pre="(VZV) (Zarrouk et al., 2017). Acyclovir is activated by the" exact="viral" post="thymidine kinase and then di- and tri-phosphorylated by cellular"/>
  <result pre="tri-phosphorylated forms of acyclovir and then specifically interferes with the" exact="viral" post="DNA polymerase and causes chain termination (Piret and Boivin,"/>
  <result pre="Cell Culture Vero and MDCK cells were obtained from the" exact="American" post="Type Culture Collection (ATCC, Rockville, MD, United States) and"/>
  <result pre="prepared in MDCK cells grown in 4% fetal bovine serum." exact="Infectious" post="virus titers were determined by titration on MDCK cell"/>
  <result pre="monolayers in 96-well plates and expressed as 50% tissue culture" exact="infectious" post="dose (TCID50) by the method of Spearman and Kärber"/>
  <result pre="polyclonal antibody directed against HSV-2 (ab21112) in combination with biotin-conjugated" exact="secondary" post="goat anti-rabbit (ab6720) and rabbit anti-sheep (ab6746) antibodies (all"/>
  <result pre="(ab6746) antibodies (all antibodies derived from Abcam, Cambridge, United Kingdom)." exact="Protein" post="was visualized using streptavidin peroxidase complex with AEC as"/>
  <result pre="were compared by ANOVA followed by the Student-Newman–Keuls test. P-values" exact="lower" post="than 0.05 were considered to be significant. Results Effects"/>
  <result pre="up to 160 μg/mL. Omeprazole concentrations of 80 μg/mL and" exact="lower" post="did not affect the viability of any of the"/>
  <result pre="Supplementary Table S1). FIGURE 1 Cytopathogenic effect (CPE) formation and" exact="viral" post="gene expression in the presence of antiviral nucleoside analogues"/>
  <result pre="cells. Vero is a continuous cell line derived from kidney" exact="epithelial" post="cells of an African green monkey (Yasumura and Kawakita,"/>
  <result pre="continuous cell line derived from kidney epithelial cells of an" exact="African" post="green monkey (Yasumura and Kawakita, 1963). Vero cells are"/>
  <result pre="cells showed that 80 μg/mL omeprazole inhibited the production of" exact="infectious" post="HSV-1 particles and that 40 and 80 μg/mL omeprazole"/>
  <result pre="that 40 and 80 μg/mL omeprazole inhibited the production of" exact="infectious" post="HSV-2 particles. In agreement with the findings from the"/>
  <result pre="this omeprazole-induced increase of acyclovir activity was also seen at" exact="lower" post="omeprazole concentrations, which did not directly reduce virus titers"/>
  <result pre="of acyclovir, a first line drug for HSV-1, HSV-2, and" exact="varicella" post="zoster virus infection (Piret and Boivin, 2016; Klysik et"/>
  <result pre="acyclovir, a first line drug for HSV-1, HSV-2, and varicella" exact="zoster" post="virus infection (Piret and Boivin, 2016; Klysik et al.,"/>
  <result pre="a first line drug for HSV-1, HSV-2, and varicella zoster" exact="virus infection" post="(Piret and Boivin, 2016; Klysik et al., 2018), in"/>
  <result pre="first line drug for HSV-1, HSV-2, and varicella zoster virus" exact="infection" post="(Piret and Boivin, 2016; Klysik et al., 2018), in"/>
  <result pre="chloroquine and ammonium chloride are known to interfere with the" exact="infection" post="of viruses including HSV. These drugs increase intracellular pH"/>
  <result pre="These drugs increase intracellular pH presumably resulting in inhibition of" exact="viral" post="packing and maturation through trans-Golgi network, although their exact"/>
  <result pre="acyclovir were more pronounced than the direct antiviral effects and" exact="lower" post="omeprazole concentrations, which did not affect HSV-1 and HSV-2"/>
  <result pre="that omeprazole increases the antiviral activity of acyclovir during the" exact="viral" post="replication cycle after infection and virus internalization. The proton"/>
  <result pre="antiviral activity of acyclovir during the viral replication cycle after" exact="infection" post="and virus internalization. The proton pump inhibitors pantoprazole, rabeprazole,"/>
  <result pre="need for improved therapies for HSV-1- and HSV-2-associated disease. After" exact="primary" post="infection, HSV-1 and HSV-2 establish life-long persistence which may"/>
  <result pre="HSV-1 and HSV-2 establish life-long persistence which may result in" exact="recurrent" post="disease which typically manifests as herpes labialis or herpes"/>
  <result pre="and HSV-2 establish life-long persistence which may result in recurrent" exact="disease" post="which typically manifests as herpes labialis or herpes genitalis"/>
  <result pre="which may result in recurrent disease which typically manifests as" exact="herpes" post="labialis or herpes genitalis and which may be associated"/>
  <result pre="in recurrent disease which typically manifests as herpes labialis or" exact="herpes" post="genitalis and which may be associated with significant morbidity"/>
  <result pre="2016; Klysik et al., 2018). Even in the case of" exact="herpes" post="labialis, which is not commonly associated with severe complications,"/>
  <result pre="as hydrocortisone but to more specifically increase acyclovir activity. In" exact="immunodeficiency" post="individuals, HSV-1 and -2 infections are often associated with"/>
  <result pre="specifically increase acyclovir activity. In immunodeficiency individuals, HSV-1 and -2" exact="infections" post="are often associated with more severe disease, and resistance"/>
  <result pre="problem (Piret and Boivin, 2016; Karrasch et al., 2018). Moreover," exact="ocular" post="HSV infection is a major cause of blindness in"/>
  <result pre="and Boivin, 2016; Karrasch et al., 2018). Moreover, ocular HSV" exact="infection" post="is a major cause of blindness in industrialized countries"/>
  <result pre="2018). Moreover, ocular HSV infection is a major cause of" exact="blindness" post="in industrialized countries (Klysik et al., 2018). Thus, more"/>
  <result pre="2018). Thus, more effective treatment options for HSV-1- and HSV-2-caused" exact="disease" post="are highly desirable. In this context, proton pump inhibitors"/>
  <result pre="that a dose increase may be feasible in a severe" exact="acute" post="disease setting. In conclusion, omeprazole and other proton pump"/>
  <result pre="a dose increase may be feasible in a severe acute" exact="disease" post="setting. In conclusion, omeprazole and other proton pump inhibitors"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseases.Pharmacol. Res. Perspect.5:e00293. 10.1002/prp2.29328596841 BalzaE.PiccioliP.CartaS.LavieriR.GattornoM.SeminoC.et al. (2016). Proton pump"/>
  <result pre="10.1002/prp2.29328596841 BalzaE.PiccioliP.CartaS.LavieriR.GattornoM.SeminoC.et al. (2016). Proton pump inhibitors protect mice from" exact="acute" post="systemic inflammation and induce long-term cross-tolerance.Cell Death Dis.7:e2304. 10.1038/cddis.2016.21827441656"/>
  <result pre="BalzaE.PiccioliP.CartaS.LavieriR.GattornoM.SeminoC.et al. (2016). Proton pump inhibitors protect mice from acute" exact="systemic" post="inflammation and induce long-term cross-tolerance.Cell Death Dis.7:e2304. 10.1038/cddis.2016.21827441656 BarrettP."/>
  <result pre="Vero cell platform in vaccine production: moving towards cell culture-based" exact="viral" post="vaccines.Expert Rev. Vaccines.8607–618. 10.1586/erv.09.1919397417 BeaucourtS.VignuzziM. (2014). Ribavirin: a drug"/>
  <result pre="of ribavirin resistance.Curr. Opin. Virol.810–15. 10.1016/j.coviro.2014.04.01124846716 BoukampP.PetrussevskaR. T.BreitkreutzD.HornungJ.MarkhamA.FusenigN. E. (1988)." exact="Normal" post="keratinization in a spontaneously immortalized aneuploid human keratinocyte cell"/>
  <result pre="Efficacy and safety of nucleoside antiviral drugs for treatment of" exact="recurrent" post="herpes labialis: a systematic review and meta-analysis.J. Oral. Pathol."/>
  <result pre="and safety of nucleoside antiviral drugs for treatment of recurrent" exact="herpes" post="labialis: a systematic review and meta-analysis.J. Oral. Pathol. Med.46561–568."/>
  <result pre="DesmyterJ.MelnickJ. L.RawlsW. E. (1968). Defectiveness of interferon production and of" exact="rubella" post="virus interference in a line of African green monkey"/>
  <result pre="production and of rubella virus interference in a line of" exact="African" post="green monkey kidney cells (Vero).J. Virol.2955–961. 4302013 GalliA.MensH.GottweinJ. M.GerstoftJ.BukhJ."/>
  <result pre="associated with increased frequency of G-to-A and C-to-U transitions in" exact="infectious" post="cell culture model.Sci. Rep.8:4619. 10.1038/s41598-018-22620-2262229545599 GhebreY. T. (2018). Proton"/>
  <result pre="of proton pump inhibitors for enhanced efficacy and safety of" exact="cancer" post="chemotherapy.Front. Pharmacol.8:911. 10.3389/fphar.2017.0091129311921 JohnsonD. C.BainesJ. D. (2011). Herpesviruses remodel"/>
  <result pre="10.1038/nrmicro255921494278 JordanP. C.StevensS. K.DevalJ. (2018). Nucleosides for the treatment of" exact="respiratory" post="RNA virus infections.Antivir. Chem. Chemother.26:2040206618764483. 10.1177/204020661876448329562753 KärberG. (1931). Beitrag"/>
  <result pre="Rapid acquisition of acyclovir resistance in an immunodeficient patient with" exact="herpes" post="simplex encephalitis.J. Neurol. Sci.38489–90. 10.1016/j.jns.2017.11.02429249385 KeppekeG. D.CaliseS. J.ChanE. K."/>
  <result pre="J. (2014). What is the future of ribavirin therapy for" exact="hepatitis" post="C?Antiviral Res.10434–39. 10.1016/j.antiviral.2014.01.00524468277 KoyamaA. H.UchidaT. (1984). Inhibition of multiplication"/>
  <result pre="C?Antiviral Res.10434–39. 10.1016/j.antiviral.2014.01.00524468277 KoyamaA. H.UchidaT. (1984). Inhibition of multiplication of" exact="herpes" post="simplex virus type 1 by ammonium chloride and chloroquine.Virology138332–335."/>
  <result pre="KoyamaA. H.UchidaT. (1984). Inhibition of multiplication of herpes simplex virus" exact="type 1" post="by ammonium chloride and chloroquine.Virology138332–335. 10.1016/0042-6822(84)90356-86093369 KoyamaA. H.UchidaT. (1989)."/>
  <result pre="(1989). The effect of ammonium chloride on the multiplication of" exact="herpes" post="simplex virus type 1 in Vero cells.Virus Res.13271–281. 10.1016/0168-1702(89)90073-72554609"/>
  <result pre="of ammonium chloride on the multiplication of herpes simplex virus" exact="type 1" post="in Vero cells.Virus Res.13271–281. 10.1016/0168-1702(89)90073-72554609 LiM. J.LiQ.SunM.LiuL. Q. (2017)."/>
  <result pre="pretreatment on resistance of solid tumors to cytotoxic drugs.J. Natl." exact="Cancer" post="Inst.961702–1713. 10.1093/jnci/djh30515547183 MartelliA.MattioliF.MeretoE.Brambilla CampartG.SiniD.BergamaschiG.et al. (1998). Evaluation of omeprazole"/>
  <result pre="Minocycline inhibits West Nile virus replication and apoptosis in human" exact="neuronal" post="cells.J. Antimicrob. Chemother.60981–986. 10.1093/jac/dkm30717872917 MontagnonB. J.Vincent-FalquetJ. C. (1998). Experience"/>
  <result pre="acyclovir and 1% hydrocortisone topical cream in the treatment of" exact="herpes" post="labialis.Skin Therapy Lett.195–8. 25188362 PiretJ.BoivinG. (2016). Antiviral resistance in"/>
  <result pre="herpes labialis.Skin Therapy Lett.195–8. 25188362 PiretJ.BoivinG. (2016). Antiviral resistance in" exact="herpes" post="simplex virus and varicella-zoster virus infections: diagnosis and management.Curr."/>
  <result pre="YasumuraY.KawakitaY. (1963). Studies on SV40 in tissue culture-preliminary step for" exact="cancer" post="research in vitro.Nihon Rinsho211201–1215. ZarroukK.PiretJ.BoivinG. (2017). Herpesvirus DNA polymerases:"/>
 </snippets>
</snippetsTree>
